Diageo ($DEO) podcast mentions
Timestamped Diageo ($DEO) mentions across our podcast corpus.
You know what looks pretty good on a consumer chart is Diageo. Organic was in line. Down to— but, Jim, but they're looking at $1 billion in restructuring savings beginning this fiscal year.
Carl Quintanilla · Squawk on the Street · 9am Hour: Dimon's Market Warning, Sandisk and Western Digital Tumble, SpaceX Lockup Expiration 8/6/26 · 2026-08-06Well, if they're going to reduce the dividend, you have 4.5%. I get that. Not bad. I like growth. They don't have it. Diageo doesn't have— remember, these are not growth vehicles. The one that I think is eventually going to have growth, it will be Constellation. And that's because you have a very, very good new CEO there, Nick Fink, who I love. And said, well, wait a second, he comes from a Foster, you know, a faucet company. No, he comes from— he comes from, from Jim Beam.
Jim Cramer · Squawk on the Street · 9am Hour: Dimon's Market Warning, Sandisk and Western Digital Tumble, SpaceX Lockup Expiration 8/6/26 · 2026-08-06Earlier today, we had our investing club monthly meeting. Where Jeff Marks and I get together and walk club members through our decision-making process for the portfolio. Oh, I tell some stories. We discuss our current holdings, then we take questions from club members. But since we never have time to get to all those, I'm giving you an inside look right now what happens at the monthly meetings, uh, while also doling out, I hope, some much-needed advice about the market. I think if you join the club, you will get insights on how to manage your portfolio. You'll get some laughs too. The stories tend to be some of the best I can Jen up. Hey, by the way, if you want to be part of the monthly meeting, which I sure do want you to be, join the club. Just scan this QR code behind me or go to cmc.com/investingclub. I save my— I save some pretty good stuff for the club, let's put it that way. Now, to start us off, we've got Daniel who asks, I bought Oracle for my Roth IRA 2 years ago at $140. Should I leave it alone or sell it and buy something else? I don't care where you bought a stock, I care where it's going to, and I think that stock is going down. It doesn't fit in for what I would consider to be an IRA. I think it's too risky. I think you should sell it. Then we have Dennis who says, with the November midterm elections close, is it better to put new money to work now as opportunities arise or wait for potential post-election pullback in the market? We buy individual companies that have stocks. If we think that the company's stock is low, we buy it. If we get another opportunity to buy it even lower from an election, we buy more. That's what we do. We are stock pickers. We are stock owners. We are not renters. Next up, we have John, who asked, the sector is taking a significant hit, but I think Diageo has historically been the best in class. Is there a point at which you would buy this beaten down stock as a long-term game? I know this liquor business cold for some other things that are involved with my life, and I've got to tell you, I would not touch any liquor company right now. There are a lot of ones— the gins, the vodkas, the browns— they're all doing terribly. You don't need to try to call a bottom. Next up, we have Wade from Texas who says Jim gets a lot of questions about speculative stocks and made money and he's always clear about allocating appropriately. The trust doesn't really have any spec positions and I'm curious if Jim would ever consider adding one. Maybe the club doesn't need it because it's doing well, but curious to take— well, it isn't. It's a charitable trust. So I always think that those shouldn't be involved. I do like speculative stocks. I hope one day to be able to talk and have some some interesting products that are about speculation, but it is not a charitable trust. Then we have Big Mike from New York. Jim, with the first half of 2026 now in the rearview mirror, what sectors do you feel offer the best investing opportunities for the remainder of 2026? I like the banks. I like the pharmaceuticals. I like— I tell you, I've got— I know it sounds crazy, but I love travel and aerospace. And then I will like tech when the big unwind is over. Particularly some of the less speculative semiconductors that I think are really great. And you're familiar with them if you watch any of the shows or stuff that we do with the club. Also, we have Joe from North Carolina who asked, what general method would you recommend to reduce the number of holdings due to a portfolio getting too large? I'm at 45 holdings and prefer to be at the 25 to 30 range. All of them are in good shape or strategic. It's going to— it's getting tough to do the necessary homework. I totally agree. I talked at the end of the club today that I have 34. I want to reduce it to 30. Rank your holdings. So 1 means you got to own it and buy more if it comes down. A 2 means you're okay with it, but you're a weak holder. A 3 means you get rid of it today. You cannot possibly have all 1s. There's nobody that has all 1s. Do that and sell the 3s. Next, we have Eric from California who says, I retired a year ago and have a large position in company stock acquired through RSUs, employee stock purchases. It's now about 10% of my total portfolio. How would you reduce the overall weighting in my portfolio since I don't think it will grow as fast as other options? Okay. You may find this to be a little counterintuitive, but 10% is actually not that much. I think you're in good shape. If you don't like the stock, by all means sell it. There's no reason to hold on to any stock that you don't like. I've got plenty of stocks in Charitable Trust. There's got to be one of those 30 and change that you do like more than what you got. The RSUs. Last but not least, we have Bob who asked, if you were to get a new puppy and wanted to name it after a public company, what would you name it? Um, well, I'd say by Tuesday I might name it Intel. Thanks again to all our club members. And Mad Money is back after the break.
Jim Cramer · Mad Money w/ Jim Cramer · Mad Money w/ Jim Cramer 7/16/26 · 2026-07-16There were a series of articles lately about how alcohol continues to go down. Carl, they're not true. Lots of different brands of alcohol have bottomed. Beer in particular. But some of the spirits have bottomed. The agave spirits have bottomed. So I see Diageo starting to go up. No, I don't expect Brown-Formigle because that's a problem with the family splitting up. I think Constellation is terrific. Someone said that they're not going to do that well because Brazil was not in the— didn't make the 16. Well, like, that's Brazil. They don't own the rights to that. And I said Bush is going up. I think that that article marked the bottom. I think that this is a group that has great cash flow. STG has great cash flow and that there is a bottom. And just like when we talk about flavoring in some foods. Some liquors have crossed over and are back, including the ready-to-drinks. So don't write off the liquor industry just yet. It's heavy.
Jim Cramer · Squawk on the Street · 9AM Hour: Amazon Plans $25B Bond Sale, Chips Slide Despite Samsung's Blowout Quarter, Bullish Calls on SpaceX 7/7/26 · 2026-07-07Exactly. We've been making beer and obviously fermented spirit, you know, for millennium. And so those are like incredibly long duration franchise. But yes, especially if you look at the US and other developed market, I think people are drinking differently, less often less casually. And so going home from work and having a beer in front of the TV I think is not the case anymore. And so we don't own beer players in developed market. I think that's a business in secular decline. But on the spirit side I think people are, are definitely drinking less, but they're also drinking differently. And so I think on the spirit side I think it's an interesting time maybe to pick up some great franchise. You've got Diageo in the UK which trade at a valuation we haven't seen quite a long time. And so in that idea of drinking less, drinking better, Diageo on a stable of very unique brand across categories really playing the premiumization trend. And when you pay, you know, like very low teens earning multiple for a business which we believe is like pretty long duration brands which are very often like century old, you know, very hard to replicate if you, if you buy cheap enough. And I think it could Be an interesting time. You know, if you go back a few years, we also bought a lot of tobacco companies at a time where people felt those were completely melting ice cube. And so we don't know exactly if and when volume do come back. We feel there's definitely some cyclical element in the volume drop you've seen in the US but we think those businesses should exist for many decades to come. And so if you buy them cheap enough and the management team use the cash intelligently, that could be interesting investment, which is why we like dipped our toes in some of those companies.
Julien Albertini · The Acquirers Podcast · The Fund That's Beaten the Market for 45 Years by Focusing on What Could Go Wrong · 2026-06-04We're back With Prof. G markets, two very different earnings stories emerged last week. And together they say a lot about where consumer behavior is headed. First, the alcohol industry continues to struggle. Diageo, the maker of Johnnie Walker and Smirnoff, reported a 9.4% decline in North American sales year over year. Constellation Brands, the company behind drinks like Corona and Modelo, painted a similar picture, citing softer demand and withdrawing its fiscal 2020 guidance. Meanwhile, the companies behind GLP1 drugs crushed their earnings. Novo Nordisk reported surging demand for its new Wegovy pill and raised its full year guidance. Eli Lilly said that revenue from Mounjaro, which is their GLP1 drug, jumped 125% year over year, more than doubled to $8.7 billion. And now the CEOs of the beverage companies did not explicitly blame GLP1s for the pain. While that is true, the correlation here is pretty clear and it's something that we have been talking about for a long time. Scott, you said as early as 2023 that alcohol would be one of the first casualties of the rise of GLP1 drugs. Let's just play a clip of what you said.
Ed Elson · Prof G Markets · AI’s New Trillion Dollar Mission_ Delete Middle Management · 2026-05-11I even saw some data saying that people on Ozempic reduced their drinking by 60%. Diageo, the alcohol government guys, oh my God. These stocks, in my opinion, are going to get absolutely hammered. We could see alcohol really taken on the chin.
Scott Galloway · Prof G Markets · AI’s New Trillion Dollar Mission_ Delete Middle Management · 2026-05-11I don't drink as much as before. I think that's definitely a trend and we can get into that just to go through some of the earnings that we saw here. So we mentioned Diageo spirit sales down 15%. Tequila sales declined double digits. Constellation Brands, they reported that wine and spirit sales were down 58%. So these companies are getting hammered in the alcohol department but we are seeing an explosion in non alcoholic sales. So AB and BEV, their non alcoholic sales grew 27% this quarter and that actually drove an overall growth in sales performance. So they are figuring out a way to avoid the alcohol boogeyman and that is stop selling alcohol and start selling non alcoholic products. But I would also like to point you to what I thought was one of the greatest quotes that we saw on CNBC last week from the AB&BEV CEO who is recognizing this trend among young people, which is that we're not so much excited about going out and getting super fucked up on alcohol, but we're more interested in these sort of healthier experiences. We're more health conscious and we'll get into that as well. And this was his pitch as to why be beer is the new healthy product. Let's just play this clip. Beer naturally has protein because the barley that we use is rich in protein.
Ed Elson · Prof G Markets · AI’s New Trillion Dollar Mission_ Delete Middle Management · 2026-05-11Whatever fatty deposits or scars are on my liver, those are badges of honor. Badges of honor. Anyways. But as I've gotten older, older, I realize my liver can't process alcohol the way it used to. So I'm trying to tone it down. But now you know. And of course I'm doing more edibles now. So I don't know. I don't know. Which supposedly creates psychosis. Andrew Huberman told me that by my age I would have discovered if it was going to cause psychosis. So I've been cleared by Huberman lab to do edibles. Oh just. So back to the, back to the whole markets part of this Joey Baggadonis podcast. So Diageo in 2016 was 100 bucks a share. Now it's 85. Okay. The S and P has had to have doubled. It should be a two or three hundred bucks. It's at 85. Brown Foreman Jack Daniels fame, 45 bucks in 2016 it's at 27. Now Anheuser Busch AB InBev was 125 bucks. Now it's 80. Heinegan 70. It's actually gone up. One of the steadier performers is at 90. Pernod Ricard was at 95. Now it's at €65. I mean this, this sector, it's hard. It would be hard to find a sector that has underperformed with such incredible brands in the drinks business. It has been a disaster over the last decade.
Scott Galloway · Prof G Markets · AI’s New Trillion Dollar Mission_ Delete Middle Management · 2026-05-11Mike's going to have to reinvent to stay relevant, I think, and he's got to do it quickly. Best Buy reports— now, this is a tricky one. We keep hearing that they'll be punished for having too many devices that are going up in price because of the cost of memory. The cost of memory, like those little semiconductors, really seems to matter these days to even the PC business or the gaming business. After the close, CrowdStrike reports. Now, this is an incredibly skilled outfit that protects a huge number of clients from cybercriminals. Its CEO, George Kurtz, is a maniac for stopping cyberterrorism, and they play offense all the time. CrowdStrike's an expensive stock, though, and it— and its price earnings multiple got compressed when Anthropic, the very aggressive business-to-business AI platform, last week invaded its turf with something that can help make agents Safer. Look, in reality, CrowdStrike doesn't actually compete with Anthropic. They're like partners for heaven's sake. So it shouldn't have been crushed like that. But the stock hasn't snapped back either because these days investors simply don't want to pay up for quality merchandise. I stand by CrowdStrike, which is why we own it for the Chappell Trust. One day soon expertise will matter again and the stock will go higher, but maybe not in time for CrowdStrike's quarter. Wednesday morning, we'd hear from a real tricky one too. A lot of tricky ones, actually. Brown-Forman. This is the maker of Jack Daniel's. I know the liquor market's gotten tough because of pesky young people who don't like to drink much and instead like to work out. And plus, there's this GOP— that's one issue. But why is the stock up more than 10% year to date? Could there be something going on here? Something good? Something is not good to its competitor, Diageo, which is doing really badly. After the close, Broadcom reports. $1.5 trillion company makes semis and software. Really doesn't get enough attention given its size. Now, some of the chips are sold to Alphabet, which is a big buyer. That said, Broadcom needs to get new clients. Right now it's caught in the software decline stemming from AI fears. I think the decline's wrong. You don't get the $1.5 trillion for doing nothing right. But you know what?
Jim Cramer · Mad Money w/ Jim Cramer · Mad Money w/ Jim Cramer 2/27/26 · 2026-02-28Hello everyone, welcome to another episode of the Dentalpreneur Podcast. I'm your host, Dr. Mark Costas, what is up, my friends? I hope winter is treating you well out there. Very excited today because I have a very esteemed guest that I'm going to be interviewing. It's his first time on the podcast. Let's welcome to the podcast Prashant Ori. Uh, he is the president of Henry Schein Canada and Americas, which is the non-US global division, uh, distribution group rather, overseeing operations across Canada, Global Lab, Brazil. With over 24 years of leadership experience in healthcare and consumer packaged goods, he's known for driving strategic growth, operational excellence, and high-performing teams. He joined Henry Schein back in 2012 and advanced through multiple senior leadership roles before assuming his current position in January of 2025. Originally from British Columbia and based in Toronto, Prashant has held leadership roles at Cybron Dental Specialties and Diageo Canada.
Speaker C · The Dentalpreneur Podcast w_ Dr. Mark Costes · 2417: The Future of Global Dental Care with Henry Schein Leadership · 2026-01-06Yeah, I would say seasoned. I think like many of us, there's always a story behind the name. And in this case, I'll share a fun story here. Yes, originally from BC, originally from a small town up north. Kitimat, and my birth name was Peter. It wasn't actually Prashant. So really cool background story there. But, you know, I've been fortunate, blessed to be in the dental space. It's— I call it the boutique industry, in the sense that people don't really think about dental in that way. They really think about healthcare. And, you know, back when I was younger, it was pharmaceuticals. But I fell in love with dental working for a company called Cyberon Endo, as you mentioned. And the name that you had troubles with, with Diageo, is a common name. You'll remember Smirnoff, you'll remember Crown Royal, remember Johnnie Walker, Guinness. It's the organization that owns all of those brands. So I moved away from adult beverages to dental. And that story began, I would say, when I chose to be different. And I wanted to get out of the alcohol beverage industry, the consumer packaged goods business. I could have stayed there and done really, really well, but I felt like the need to just work for an organization where there was purpose and where I could align my own personal purpose with— really, I was unpacking at that young age, still trying to figure out what that looked like, but I knew that I had done what I needed to do at Diageo and needed to move on. And so I moved from the liquor business to a root canal rep role, not knowing too much about dental and not knowing too much about root canals. But it was definitely a way to put my wife at that time to sleep by talking about root canal therapy, whether it was canal shaping or irrigation. But, you know, definitely a wonderful opportunity to get into the business and understand it. From a specialty standpoint. You really immerse yourself in a narrow focus versus being broad, being a liquor beverage expert at that time. And then I got to a point where I left Saibron Endo. For me, it was innovation was lacking, and there was also changes within the organization at that time.
Speaker D · The Dentalpreneur Podcast w_ Dr. Mark Costes · 2417: The Future of Global Dental Care with Henry Schein Leadership · 2026-01-06